A Karlén

发表

Characterization of a Set of HIV-1 Protease Inhibitors Using Binding Kinetics Data from a Biosensor-Based Screen

L. Vrang, B. Samuelsson, A. Hallberg, 2000, Journal of biomolecular screening.

Competitive CYP2C9 inhibitors: enzyme inhibition studies, protein homology modeling, and three-dimensional quantitative structure-activity relationship analysis.

C. Masimirembwa, T. Andersson, I. Zamora, 2001, Molecular pharmacology.

Cyclic HIV-1 protease inhibitors derived from mannitol: synthesis, inhibitory potencies, and computational predictions of binding affinities.

J. Åqvist, J. Hulten, B. Samuelsson, 1997, Journal of medicinal chemistry.

SPR biosensor studies of the direct interaction between 27 drugs and a liposome surface: correlation with fraction absorbed in humans.

H Lennernäs, M. Hämäläinen, A. Hansson, 2000, Journal of medicinal chemistry.

Correlation of human jejunal permeability (in vivo) of drugs with experimentally and theoretically derived parameters. A multivariate data analysis approach.

H Lennernäs, A. Hallberg, S. Winiwarter, 1998, Journal of medicinal chemistry.

Synthesis and comparative molecular field analysis (CoMFA) of symmetric and nonsymmetric cyclic sulfamide HIV-1 protease inhibitors.

J. Hulten, B. Samuelsson, A. Hallberg, 2001, Journal of medicinal chemistry.

C3-methylated 5-hydroxy-2-(dipropylamino)tetralins: conformational and steric parameters of importance for central dopamine receptor activation.

A Carlsson, A Karlén, U Hacksell, 1987, Journal of medicinal chemistry.

Dopaminergic 2-aminotetralins: affinities for dopamine D2-receptors, molecular structures, and conformational preferences.

A Karlén, U Hacksell, C J Grol, 1986, Molecular pharmacology.

Unexpected binding mode of a cyclic sulfamide HIV-1 protease inhibitor.

K Osterlund, J. Hulten, A. Hallberg, 1997, Journal of medicinal chemistry.